CROHN’S DISEASE: CURRENT INSIGHTS INTO PATHOGENESIS, DIAGNOSIS AND TREATMENT

Background: Crohn’s disease (CD) is a chronic, relapsing inflammatory bowel disease with rising global incidence and substantial long-term morbidity. Its heterogeneous clinical course reflects a complex interplay between genetic susceptibility, environmental factors, intestinal dysbiosis, epithelial barrier dysfunction, and dysregulated immune responses. Advances in diagnostics and therapeutics have transformed CD management, yet disease progression and complications remain common. Methods: This narrative review synthesizes current evidence on the pathophysiology, clinical presentation, diagnostic strategies, and treatment of Crohn’s disease. Peer-reviewed literature was examined focusing on genetic and immunological mechanisms, microbiome alterations, diagnostic modalities, conventional and advanced therapies, nutritional and surgical management, and emerging experimental approaches. Results: Crohn’s disease pathogenesis involves polygenic risk factors (e.g., NOD2, ATG16L1, IL23R), impaired autophagy, dysbiosis, and aberrant innate and adaptive immune activation. Diagnosis requires an integrated approach combining biomarkers, endoscopy with histology, and cross-sectional imaging. Therapeutic strategies have shifted toward a treat-to-target model, emphasizing mucosal healing through biologics, small-molecule agents, immunomodulators, and selected nutritional interventions. Novel microbiome and cell-based therapies show promise but remain investigational. Conclusion: Despite major therapeutic advances, Crohn’s disease continues to impose significant disease burden. Early diagnosis, proactive treatment, and personalized, mechanism-based strategies are essential to prevent cumulative bowel damage. Ongoing research into precision medicine and microbiome-targeted therapies may further improve long-term outcomes.

Authors

Institutions

Publication Details

Journal
International Journal of Innovative Technologies in Social Science
Published
2025-12-30
DOI
https://doi.org/10.31435/ijitss.4(48).2025.4666
Primary Topic
Inflammatory Bowel Disease
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

CROHN’S DISEASE: CURRENT INSIGHTS INTO PATHOGENESIS, DIAGNOSIS AND TREATMENT

Karol Grela, Karolina Nowacka, Weronika Radecka, Kamil Jabłoński et al.
International Journal of Innovative Technologies in Social Science
Inflammatory Bowel Disease
article

CROHN’S DISEASE: CURRENT INSIGHTS INTO PATHOGENESIS, DIAGNOSIS AND TREATMENT

Karol Grela, Karolina Nowacka, Weronika Radecka, Kamil Jabłoński, Klaudia Baran, Agnieszka Szreiber, Anna Woźniak, Michał Ględa, Aleksandra Grygorowicz, Weronika Kozak, Michał Szyszka
article en

Abstract

Background: Crohn’s disease (CD) is a chronic, relapsing inflammatory bowel disease with rising global incidence and substantial long-term morbidity. Its heterogeneous clinical course reflects a complex interplay between genetic susceptibility, environmental factors, intestinal dysbiosis, epithelial barrier dysfunction, and dysregulated immune responses. Advances in diagnostics and therapeutics have transformed CD management, yet disease progression and complications remain common. Methods: This narrative review synthesizes current evidence on the pathophysiology, clinical presentation, diagnostic strategies, and treatment of Crohn’s disease. Peer-reviewed literature was examined focusing on genetic and immunological mechanisms, microbiome alterations, diagnostic modalities, conventional and advanced therapies, nutritional and surgical management, and emerging experimental approaches. Results: Crohn’s disease pathogenesis involves polygenic risk factors (e.g., NOD2, ATG16L1, IL23R), impaired autophagy, dysbiosis, and aberrant innate and adaptive immune activation. Diagnosis requires an integrated approach combining biomarkers, endoscopy with histology, and cross-sectional imaging. Therapeutic strategies have shifted toward a treat-to-target model, emphasizing mucosal healing through biologics, small-molecule agents, immunomodulators, and selected nutritional interventions. Novel microbiome and cell-based therapies show promise but remain investigational. Conclusion: Despite major therapeutic advances, Crohn’s disease continues to impose significant disease burden. Early diagnosis, proactive treatment, and personalized, mechanism-based strategies are essential to prevent cumulative bowel damage. Ongoing research into precision medicine and microbiome-targeted therapies may further improve long-term outcomes.

International Journal of Innovative Technologies in Social ScienceVol. 2(4(48))
Medical University of Silesia (PL), Medical University of Warsaw (PL), Medical University of Lodz (PL), Uczelnia Łazarskiego (PL), Silesian Center for Heart Disease (PL), University of Warmia and Mazury in Olsztyn (PL), Cardinal Stefan Wyszynski University in Warsaw (PL), Gdańsk Medical University (PL)
Zero hunger
Openalex Percentile: Top 23%
Inflammatory Bowel Disease
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.